Skip Nav Destination
Issues
15 January 2009
-
Cover Image
Cover Image
A multiplex tissue immunoblotting analysis of phospho-mTOR in extrahepatic cholangiocarcinoma. Multiplex tissue immunoblotting is a method of transferring proteins from a formalin-fixed, paraffin-embedded tissue section to a stack of replicate membranes, which can then be probed with antibodies by conventional immunoblotting methods. Using this approach, total protein and target antigen signals can be simultaneously determined on each membrane as a means of normalization. As the membranes are replicates, ratio-based measurements of different target antigens can be made. The cover image is a scan of a single membrane, probed with a fluorescent secondary antibody, showing the relative signal as visualized by pseudo-color, where signal intensity is white-red-yellow-green-blue-black from maximum to minimum signal. The ratios of different proteins in the AKT pathway predict survival in extrahepatic cholangiocarcinoma. For further details, please see Chung and coworkers on page 660 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Review
Human Cancer Biology
Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
Fabrice Andre; Bastien Job; Philippe Dessen; Attila Tordai; Stefan Michiels; Cornelia Liedtke; Catherine Richon; Kai Yan; Bailang Wang; Gilles Vassal; Suzette Delaloge; Gabriel N. Hortobagyi; W. Fraser Symmans; Vladimir Lazar; Lajos Pusztai
Targeted Knockdown of Notch1 Inhibits Invasion of Human Prostate Cancer Cells Concomitant with Inhibition of Matrix Metalloproteinase-9 and Urokinase Plasminogen Activator
Bilal Bin Hafeez; Vaqar Mustafa Adhami; Mohammad Asim; Imtiaz A. Siddiqui; Kumar M. Bhat; Weixiong Zhong; Mohammad Saleem; Maria Din; Vijayasaradhi Setaluri; Hasan Mukhtar
Cancer Therapy: Preclinical
Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma
Guido Bisping; Doris Wenning; Martin Kropff; Dirk Gustavus; Carsten Müller-Tidow; Matthias Stelljes; Gerd Munzert; Frank Hilberg; Gerald J. Roth; Martin Stefanic; Sarah Volpert; Rolf M. Mesters; Wolfgang E. Berdel; Joachim Kienast
Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2
Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G. Vile
Imaging, Diagnosis, Prognosis
Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer
Stephan Macher-Goeppinger; Sebastian Aulmann; Katrin E. Tagscherer; Nina Wagener; Axel Haferkamp; Roland Penzel; Antje Brauckhoff; Markus Hohenfellner; Jaromir Sykora; Henning Walczak; Bin T. Teh; Frank Autschbach; Esther Herpel; Peter Schirmacher; Wilfried Roth
Cancer Therapy: Clinical
Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma
Alberto Broniscer; Suzanne J. Baker; Clinton F. Stewart; Thomas E. Merchant; Fred H. Laningham; Paula Schaiquevich; Mehmet Kocak; E. Brannon Morris; Raelene Endersby; David W. Ellison; Amar Gajjar
Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma
Mark A. Dawson; Stephen S. Opat; Yamna Taouk; Mark Donovan; Michele Zammit; Katherine Monaghan; Noemi Horvath; Andrew W. Roberts; H. Miles Prince; Mark Hertzberg; Catriona A. McLean; Andrew Spencer
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Alain C. Mita; Louis J. Denis; Eric K. Rowinsky; Johann S. DeBono; Andrew D. Goetz; Leonel Ochoa; Bahram Forouzesh; Muralidhar Beeram; Amita Patnaik; Kathleen Molpus; Dorothée Semiond; Michèle Besenval; Anthony W. Tolcher
Cancer Prevention and Susceptibility
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.